Quakertown, PA, United States
Quakertown, PA, United States

Time filter

Source Type

Patent
Signpath Pharma | Date: 2016-09-14

The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy; and administering to the human or animal subject a therapeutically effective amount of a composition comprising: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma.


The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.


The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy; and administering to the human or animal subject a therapeutically effective amount of a composition comprising: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma.


Patent
Signpath Pharma and Avanti Polar Lipids Inc. | Date: 2015-06-03

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.


Patent
University of North Texas Health Science Center and Signpath Pharma | Date: 2015-05-29

The present invention includes compositions and methods of making a nanoparticle composition comprising a polymeric core comprising one or more polymers and one or more active agents, and at least one layer of one or more lipids on the surface of the polymeric core; more specifically, the invention relates to the use of curcumin within such a lipid-polymer nanoparticle formulation for minimizing QT prolongation associated with curcumin in treatment of cancer.


Patent
Signpath Pharma | Date: 2016-03-28

The present invention includes a method of treating an intervertebral disease or condition comprising: identifying a patient in need of treatment for the intervertebral disease or condition; and administering to the patient an amount of an anti-inflammatory agent that causes a cardiac channelopathy, such as curcumin, and a liposome, wherein the liposome is provided in an amount sufficient to reduce or eliminate the cardiac channelopathy caused by the anti-inflammatory agent, and the anti-inflammatory agent is provided in an amount sufficient to treat or ameliorate the symptoms of the intervertebral disease or condition.


Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.


Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.


The present invention includes a stabilized curcumin composition. The composition includes a curcumin composition and a phosphate composition, wherein the phosphate composition is non-buffering and is provided in an amount sufficient to stabilize and/or prevent the degradation of curcumin and/or a curcuminoid in a biological sample.


Patent
Signpath Pharma and Avanti Polar Lipids Inc. | Date: 2015-12-30

The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.

Loading Signpath Pharma collaborators
Loading Signpath Pharma collaborators